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Growth differentiation factor 15 (GDF-15), a member of the transforming growth factor-β superfamily, participates in processes
associated with myeloma development and its end-organ complications. It plays a significant role in both physiological and
abnormal erythropoiesis and regulates iron homeostasis through modulation of hepcidin. It is abnormally secreted in marrow
stromal cells of patients with multiple myeloma (MM), which may reflect the tumor microenvironment. We analyzed the
associations of serum GDF-15 with clinical characteristics of 73 MM patients (including asymptomatic MM) and the laboratory
indices of renal function, anemia, and inflammation. Baseline serum GDF-15 was studied as the predictor of two-year survival.
We defined five clinically relevant subgroups of patients (symptomatic MM only, patients with and without remission, patients
on chemotherapy, and without treatment). Increased GDF-15 concentrations were associated with more advanced MM stage,
anemia, renal impairment (lower glomerular filtration and higher markers of tubular injury), and inflammation. Most of the
results were confirmed in the subgroup analysis. Serum cystatin C and urine neutrophil gelatinase-associated lipocalin were
associated with GDF-15 independently of other variables. In the studied MM patients, GDF-15 did not significantly predict
survival (p = 0:06). Our results suggest that serum GDF-15 reflects myeloma burden and shares a relationship with several
markers of prognostic significance, as well as major manifestations.
1. Introduction
Multiple myeloma (MM) is a common malignant condition
resulting from a clonal proliferation of plasma cells in the
bone marrow, which manifests itself with organ involvement,
such as bone disease, anemia, and renal failure [1]. Unfortu-
nately, despite several therapeutic advances introduced in
recent years, MM remains an incurable condition for the
majority of patients ([2, 3]; T. [4]). The disease microenvi-
ronment (ME) has become a focus of research, in which cel-
lular interactions, growth factors, and cytokines have
emerged as targets of interest [1]. Growth differentiation
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factor 15 (GDF-15; also known as macrophage inhibitory
cytokine 1) has been recognized among the top interest can-
cer biomarkers [5]. The potential utility of GDF-15 in malig-
nant neoplastic disease can be drawn from its unique
characteristics of being a downstream target of tumor sup-
pressor p53, with its only physiological presence at high
levels in the placenta [6]. However, GDF-15 is also consid-
ered a divergent member of the transforming growth factor
β (TGFβ) family, which is induced in response to factors
instigating cellular stress (e.g., hypoxia, tissue injury, and
inflammation). These characteristics of GDF-15 suggest its
increased concentration may be considered as an integrative,
general marker for disease severity and mortality [6, 7].
Studies have attempted to elucidate the complex land-
scape of the myeloma ME. Schneiderova et al. [8] utilized
an array of 92 cancer biomarkers among patients with overt
myeloma and its premalignant stage, as well as an assessment
following autologous stem cell transplant (auto-SCT). Pro-
survival and chemoprotective factors were identified using
highly sensitive immunoassays, among which GDF-15 was
a prominent molecule, significantly enhanced in MM when
comparing to monoclonal gammopathy of undetermined
significance (MGUS). Westhrin et al. studied the potential
of GDF-15, through its involvement with osteoclast differen-
tiation, as a serum marker for bone lesions in MM [9]. Sub-
sequent studies by Windrichova et al. utilized multiplex
analytic technology to identify novel biomarkers for metasta-
tic bone lesions, discerning GDF-15 as the most prominent
biomarker [10]. It has been argued that improved under-
standing of the relationships between neoplastic plasmocytes
and cells and factors constituting a disease-defining ME
(interactions between the bone marrow and neoplastic cells,
secretion of cytokines, survival, and growth factors) may elu-
cidate myeloma pathophysiology, including mechanisms
responsible for treatment failure [8].
Corre et al. (J. [11]) reported that among several estab-
lished prognostic factors (including staging according to the
International Staging System—ISS), in multivariate analysis,
GDF-15 remained the only significant predictor of event-
free survival, while in vitro experiments showed pretreatment
with GDF-15 leads to improved survival of both stroma-
dependent and independent MM cells when exposed to sta-
ple drugs in the MM treatment armamentarium (i.e., mel-
phalan, bortezomib, lenalidomide). Furthermore, Mei et al.
previously reported that both plasma GDF-15 concentrations
andmRNA expression in peripheral blood mononuclear cells
(PBMCs) were enhanced in ISS-III when comparing with
stages I-II [12]. Taken together, the data presented in the lit-
erature support the relationship of GDF-15 with myeloma
burden and disease progression.
Considering the attention that GDF-15 has received as a
potential prognostic biomarker in neoplastic disease, we
examined the serum concentrations of GDF-15 in an ambu-
latory population within the continuum of MM, ranging
from asymptomatic up to overt MM (staged according to
ISS). Our aim was to assess the relationships between the
serum concentrations of GDF-15 and the disease characteris-
tics defining the clinically relevant subgroups of patients.
Moreover, we studied the correlations between GDF-15 and
the acclaimed and emerging biomarkers of important clinical
manifestations of MM, i.e., anemia and renal impairment.
Finally, we searched for the association between serum
GDF-15 and mortality in a heterogenous group of MM
patients.
2. Materials and Methods
2.1. Study Design and Patients. Patients were recruited using
convenience sampling during ambulatory control visits at the
Departments of Hematology and Nephrology of the Univer-
sity Hospital in Kraków, Poland, between August 2016 and
October 2017. The inclusion criteria were (1) age ≥ 18 years
and (2) a diagnosis of SMM or MM according to the Interna-
tional Myeloma Working Group. Patients were excluded if
any of the following were present: recent active infection; a
history of hepatitis B, C, HIV; and neoplasms other than
myeloma. Twenty-one healthy volunteers among physicians
and medical staff (11 women, 10 men) aged between 24 and
69 years were recruited into the control sample. Physicians
collected detailed history from all patients, which was supple-
mented by data from the available medical records. The data
collected at the initial study visit included the age and sex, the
date of initial diagnosis of SMM or MM, the current diagno-
sis, the results of bone imaging, and the information about
past and present treatment including the response to treat-
ment (CR, PR, SD, PD). In November 2018, the follow-up
data were collected on mortality.
The study was conducted according to the principles of
the Declaration of Helsinki and in compliance with the Inter-
national Conference on Harmonization/Good Clinical Prac-
tice regulations. The study was approved by the Bioethics
Committee of the Jagiellonian University, and all patients
signed an informed consent for participation in the study.
2.2. Blood Samples and Laboratory Tests. Blood samples were
obtained from patients at study inclusion. The blood samples
of both patients and control subjects were collected in the
morning following overnight fasting and rest. Routine labo-
ratory tests were performed on the day of blood collection
and included complete blood counts, serum concentrations
of creatinine, iron, total protein, albumin, β2-microglobulin,
free light chains, serum activity of lactate dehydrogenase, and
urine concentrations of light chains.
In all patients, the aliquots of serum samples and urine
samples were frozen and used for nonroutine laboratory
tests, including the serum concentrations of GDF-15, IL-6,
cystatin C, hepcidin, and N-terminal prohormone of brain
natriuretic peptide and urine concentrations of NGAL
monomer and cystatin C.
The Sysmex XE 2100 analyser (Sysmex, Kobe, Japan) was
used for complete blood counts. The routine biochemical
tests were carried out using automatic biochemical analysers:
Hitachi 917 (Hitachi, Japan) andModular P (Roche Diagnos-
tics, Mannheim, Germany). The eGFR was calculated based
on serum creatinine using the Modification of Diet in Renal
Disease (MDRD) formula: eGFR =
ð186 × serum creatinine ðμmol/lÞ × 0:0113Þ−1:154 × age−0:203
× 114 ð× 0:742 for womenÞ. The concentration of serum
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FLC, urine LC (κ and λ type), and β2-microglobulin were
measured by the immunonephelometric method on a BN II
analyser (Siemens GmbH, Germany). The determination of
free light chains (FLC Κ, FLC Λ) was performed using Free-
lite reagents (Binding Site, Birmingham, UK) with reference
ranges of 1.7-3.7 g/l and 0.9-2.1 g/l, respectively. The immu-
nophenotype of monoclonal protein was determined by
serum immunofixation (IFE) on agarose gel (EasyFix G26,
Interlab, Italy).
The nonroutine laboratory tests were performed in series,
using commercially available immunoenzymatic test kits.
Serum IL-6 was measured using the Quantikine ELISA
Human IL-6 Immunoassay (R&D Systems, Inc., Minneapo-
lis, USA), with the minimum detectable dose of 0.70 pg/ml
and the intra- and interassay precision of 2.0% and 3.8%,
respectively. The reference range for IL-6 was 3.13–
12.5 pg/ml. Serum GDF-15 was measured using the Quanti-
kine ELISA Human GDF-15 Immunoassay (R&D Systems,
Inc., Minneapolis, USA), with the minimum detectable dose
ranging from 0.0 to 4.4 pg/ml and the intra- and interassay
precision of 2.8% and 5.6%, respectively. The reference range
for GDF-15 was 337–1060 pg/ml. Serum hepcidin 25 levels
were measured using the Hepcidin 25 human Cet. No. S-
1337 kit (Peninsula Laboratories International, Inc., San Car-
los, USA). The reference range for hepcidin 25 is 0.02-
25 pg/ml. Urine NGAL monomer was assessed using the
Human NGAL monomer-specific ELISA kit (BioPorto Diag-
nostics A/S, Hellerup, Denmark), with the minimum detect-
able dose of 10 pg/ml. The detection range for NGAL 10-
1000 pg/ml. NT-pBNP concentrations in serum were mea-
sured by the Enzyme-linked Immunosorbent Assay Kit For
NT-ProBNP Human (Cloud-Clone Corporation, Huston,
USA), with the minimum detectable dose of 11.7 pg/ml, the
quantification range of 30.9-2.500 pg/ml, and the intra- and
interassay precision of 10% and 12%, respectively. Cystatin
C concentrations in urine and serum were measured using
Human Cystatin C ELISA (BioVendor Research and Diag-
nostic Products, Brno, Czech Republic), with the detection
range of 0.25–25 ng/ml and the intra- and interassay preci-
sion of 3.5% and 10.4%, respectively.
This study was conducted with the use of the equipment
purchased by the Medical University of Bialystok as part of
the RPOWP 2007-2013 funding, Priority I, Axis 1.1, contract
No. UDA-RPPD.01.01.00-20-001/15-00 dated 26.06.2015.
2.3. Statistical Analysis. The number of patients and the per-
centage of the studied group were reported for categories.
Mean ± standard deviation was reported for normally dis-
tributed and median (lower-upper quartile) for nonnormally
distributed quantitative variables. Shapiro-Wilk’s test was
used to assess normality. The GDF-15 concentrations (a non-
normally distributed variable) were compared between sub-
groups using Mann-Whitney’s test (two subgroups) or
Kruskal-Wallis ANOVA (more than two subgroups). The
boxplots illustrating the differences between subgroups show
the median (central line), interquartile range (box), nonout-
lier range (whiskers), and outliers (points) in each subgroup.
The Spearman rank correlation coefficient was used to assess
simple correlations of GDF-15. Right-skewed variables were
transformed using normal logarithm (ln) to increase the
readability of the scatterplots illustrating the simple correla-
tions. Also, ln-transformed right-skewed variables were used
to calculate linear regression models presented in Table 1.
Simple and multiple Cox proportional hazard regression
was used to study the predictors of overall mortality. In gen-
eral, the regression models (linear and Cox) were constructed
using predictor variables that were significantly associated
with the outcome variable in the simple analysis. In case of
multiple intercorrelated predictor variables (linear regres-
sion), we chose the ones that were most strongly correlated
with the dependent variable. The statistical tests were two-
tailed, and p < 0:05 indicated statistical significance. Statistica
12.0 (StatSoft, Tulsa, USA) was used for computations.
3. Results
3.1. Demographic and Clinical Characteristics of the Studied
Patients with Multiple Myeloma. The prospective study
recruited patients diagnosed with MM, assessed during their
control ambulatory visits between August 2016 and October
2017. Seventy-three patients with MM (35 women, 38 men)
aged between 29 and 90 years were enrolled in the study
(Table 2). Smoldering myeloma (SMM) was diagnosed in
six patients and MM in 67 patients. Most patients were in
stage I according to the International Staging System (ISS)
(Table 2) [13]. Except for 8 patients (including the subjects
diagnosed with SMM), all patients underwent at least one
line of treatment, and over one-third underwent autologous
bone marrow transplantation before entering the study. At
the start of the study, roughly 70% of patients were in com-
plete or partial remission (Table 2).
Bone lesions were observed in 60% of patients (Table 2).
Six patients experienced acute kidney injury prior to enroll-
ment, and the estimated glomerular filtration rate (eGFR)
below 60ml/min/1.73m2 was observed in 26 patients (36%)
at recruitment (Table 3). Nearly one-fifth of the patients
had low hemoglobin concentrations at the start of the study
(Table 3).
3.2. Circulating GDF-15 Is Elevated in Multiple Myeloma and
Associated with ISS Stage. Twenty-one healthy volunteers
matched with the patients according to sex (8 women, 13
men; p = 0:3 versus studied group) and age range (39 to 66
years) were recruited to provide blood samples in order to
obtain reference values for nonroutine biomarker assays.
Aside from GDF-15 and IL-6, the remaining markers
(Table 4) were not significantly altered in MM patients when
compared to healthy reference subjects. Although the mean
age of controls (51 ± 9 years) was lower compared to the
studied group (p < 0:001); the differences in GDF-15
(p = 0:018) and interleukin 6 (p = 0:049) concentrations
between MM patients and controls were independent of age.
The serum concentrations of GDF-15 were positively
correlated with the ISS stage (R = 0:65; p < 0:001) and dif-
fered significantly between patients across stages of MM
(Figure 1(a)). In post hoc comparisons, patients with ISS
stage II or III differed significantly from those with smolder-
ing myeloma or stage I MM, and only patients with
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smoldering MM did not differ significantly from controls.
Patients with complete remission (CR) had lower GDF-15
concentrations than the rest of the group: the median (lower;
upper quartile) of GDF-15 was 1029 (758; 1402) pg/ml in CR
versus 1390 (925; 2466) pg/ml in the remaining patients
(p = 0:013). However, there were no significant differences
regarding the GDF-15 concentrations between MM patients
with partial remission (PR), stable disease (SD), or progres-
sive disease (PD): 1545 (1014; 2216) pg/ml in PR; 910 (653;
3018) pg/ml in SD, and 1681 (1168; 2921) in PD (p = 0:7).
No statistically significant correlations were observed
between circulating GDF-15 and age (R = 0:22; p = 0:065)
as well as time from MM diagnosis (R = −0:16; p = 0:2).
The patients who received maintenance chemotherapy treat-
ment at the start of the study had higher circulating GDF-15
levels compared to those without treatment (Figure 1(b));
however, complete remission was more common in
untreated patients (44% versus 10% among those receiving
treatment; p = 0:002). The details regarding treatment regi-
mens (Table S1) and GDF-15 concentrations according to
drugs used (Figure S1) are shown in Supplementary File.
In MM patients, serum GDF-15 positively correlated
with the concentrations of involved (i.e., κ in patients with
monoclonal protein including κ-type light chains and λ in
patients with λ-type monoclonal protein) free light chains
in serum (R = 0:33; p = 0:004; Figure 2(a)) and involved light
chains in urine (R = 0:35; p = 0:002) as well as with total (κ
plus λ) serum free light chains (R = 0:35; p = 0:002) and urine
light chains (R = 0:37; p = 0:001). Moreover, GDF-15 con-
centrations were highly positively correlated with β2-micro-
globulin (R = 0:67; p < 0:001; Figure 2(b)) and negatively
with serum albumin (R = −0:52; p < 0:001). We defined five
subgroups of patients according to important clinical fea-
tures as recorded at the start of the study: (1) patients with
symptomatic MM (i.e., after excluding those with SMM)
(n = 67), (2) patients in remission (CR/PR) (n = 52) and (3)
those without remission (SD/PD) (n = 21), and (4) patients
receiving maintenance treatment (n = 30) and (5) not receiv-
ing chemotherapy (n = 43). In all subgroups, we confirmed
positive correlations between GDF-15 and β2-microglobulin,
and negative correlations between GDF-15 and albumin.
Free light chains in serum and light chains in urine correlated
with GDF-15 in patients with symptomatic MM, in remis-
sion, and those not receiving chemotherapy (Table S2,
Supplementary File).
3.3. Circulating GDF-15 Is Associated with Anemia in
Multiple Myeloma. Serum GDF-15 concentrations were sig-
nificantly higher in the studied patients with anemia and
inversely correlated with blood hemoglobin and serum iron
(Figures 3(a), 3(b), and 3(d)). The association between
GDF-15 and blood hemoglobin was significant in all studied
subgroups. Moreover, the association between GDF-15 and
iron was confirmed in subgroup analyses: after excluding
patients with SMM, in patients on chemotherapy and in
patients with complete or partial remission. In the study
group overall, a weak positive correlation was found between
GDF-15 and serum hepcidin-25 (Figure 3(c)). In MM
patients without remission (SD/PD), this association was
much stronger (R = 0:56; p = 0:008), while in other sub-
groups, it was nonsignificant.
3.4. Circulating GDF-15 Is Associated with Renal Function in
Multiple Myeloma. Higher GDF-15 concentrations were
observed in patients with eGFR < 60ml/min/1:73m2 as com-
pared to patients with better kidney function (p < 0:001;
Figure 4(a)). Highly significant positive correlations were
observed between serum GDF-15 and markers of glomerular
filtration: serum creatinine (R = 0:57; p < 0:001) and serum
cystatin C (R = 0:70; p < 0:001; Figure 4(b)). Consequently,
negative correlations were observed between GDF-15 and
eGFR values based on these markers (R = −0:54, p < 0:001;
Table 1: Multiple regression models showing the independent predictors of serum GDF-15 among the studied patients with MM. The right-
skewed variables (including GDF-15) were ln-transformed before analysis.
Independent
variable
Model 1 Model 2
Standardized regression coefficient ± standard error p
value
Standardized regression coefficient ± standard error p
value
SMM −0:06 ± 0:09 0.5 Not included -
ISS II 0:42 ± 0:10 <0.001 0:13 ± 0:09 0.1
ISS III 0:55 ± 0:09 <0.001 0:13 ± 0:09 0.2
SD/PD −0:06 ± 0:10 0.5 Not included -
On CTx
treatment
0:25 ± 0:10 0.012 0:13 ± 0:07 0.07
Hemoglobin Not included - −0:11 ± 0:08 0.2
ln (interleukin
6)
Not included - 0:14 ± 0:08 0.08
ln (cystatin C) Not included - 0:43 ± 0:11 <0.001
ln (uNGAL) Not included - 0:25 ± 0:08 0.002
Whole model Adjusted R2 = 0:44 <0.001 Adjusted R2 = 0:70 <0.001
CTx: chemotherapy; ISS: International Staging System for multiple myeloma; PD: progressive disease; SD: stable disease; SMM: smoldering myeloma; uNGAL:
urine neutrophil gelatinase-associated lipocalin.
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and R = −0:67, p < 0:001, respectively). These associations
were confirmed in all studied subgroups of patients (after
exclusion of SMM, with and without remission, on chemo-
therapy, and without chemotherapy). Moreover, in the study
group overall, GDF-15 concentrations positively correlated
with the studied markers of tubular injury: urine NGAL
monomer (Figure 4(c)) and urine cystatin C (R = 0:24; p =
0:040), although the latter correlation was weak. Of note, uri-
nary NGAL (R = −0:31; p = 0:008) but not urinary cystatin C
was significantly correlated with eGFR. The association
between GDF-15 and urine NGAL was significant in every
subgroup, while the correlation between GDF-15 and urine
cystatin C was only significant in patients without remission
(SD/PD) (R = 0:51; p = 0:016).
3.5. Other Variables Significantly Associated with Circulating
GDF-15 in MM and Multiple Regression. In the studied
group, weak positive correlations were observed between
the marker of systemic inflammation, interleukin 6 (IL-6),
and GDF-15 (R = 0:31; p = 0:007). Interestingly, the total
white blood cell counts and GDF-15 (R = 0:27; p = 0:022)
were significantly correlated. Both correlations were also sig-
nificant after excluding subjects with SMM; moreover, GDF-
15 was significantly correlated with IL-6 in subjects without
remission and those not on chemotherapy.
Circulating GDF-15 was weakly positively correlated
with serum NT-proBNP (R = 0:28; p = 0:016) in the whole
studied group and after the exclusion of SMM patients.
Using the data of all the studied patients, we performed
multiple regression analysis in order to assess which variables
are associated with GDF-15 concentrations independently of
each other (Table 1). Firstly, among the clinical characteris-
tics describing MM state which were associated with GDF-
15 in simple analysis, the ISS stage together with chemother-
apy treatment status was identified as independent predictors
of GDF-15 (Table 1, model 1). Secondly, laboratory data were
Table 2: Demographic and clinical characteristics of patients at baseline.
Characteristic MM patients (n = 73)
Mean age ± standard deviation, years 69 ± 10
Male sex, n (%) 38 (52)
Median time since diagnosis of MM (lower; upper quartile), months 36 (17; 69)
Smoldering myeloma, n (%) 6 (8)
ISS stage I, n (%) 40 (55)
ISS stage II, n (%) 15 (21)
ISS stage III, n (%) 12 (16)
Immunophenotype
IgG, n (%) 52 (71)
IgA, n (%) 17 (23)
IgM, n (%) 1 (1)
Biclonal, n (%) 2 (3)
Free light chains only, n (%) 1 (1)
Nonsecretory, n (%) 3 (4)
Disease state on the day of study visit
CR, n (%) 22 (30)
PR, n (%) 30 (41)
SD, n (%) 6 (8)
PD, n (%) 15 (21)
Chemotherapy on the day of study visit
On (maintenance) treatment, n (%) 30 (41)
No treatment, n (%) 43 (59)
Number of prior treatment schemes
No treatment, n (%) 8 (11)
1, n (%) 17 (23)
2, n (%) 22 (30)
3 and more, n (%) 26 (36)
History of auto-PBSCT, n (%) 28 (38)
Bone lesions, n (%) 44 (60)
History of acute kidney injury, n (%) 6 (8)
CR: complete remission; Ig: immunoglobulin; ISS: International Staging System for multiple myeloma; MM: multiple myeloma; n: number of patients; PBSCT:
peripheral blood stem cell transplant; PD: progressive disease; PR: partial remission; SD: stable disease.
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added to these predictors, and the markers of kidney func-
tion, i.e., serum cystatin C and urine NGAL monomer, were
identified as significant predictors of serum GDF-15, inde-
pendent of ISS, treatment status, hemoglobin, and interleu-
kin 6 (Table 1, model 2).
3.6. Association of GDF-15 with Mortality. In November
2018, the follow-up data on all-cause mortality were col-
lected. The median (lower; upper quartile) observation time
in the studied group was 20 (16; 23) months, range from 1
to 25 months. During the observation period, 15 (21%)
patients died. Two-year survival (calculated from recruit-
ment into the study until death or the end of follow-up)
was 79%. ISS stage (II or III versus I) and positive chemother-
apy status on recruitment were identified as significant pre-
dictors of worse survival. GDF-15 (ln-transformed) was not
significantly associated with overall survival, neither in sim-
ple analysis nor after adjustment for these predictors; how-
ever, the association was close to being statistically
significant (Table 5). Notably, the direction of this associa-
tion changed from negative in the simple analysis (HR higher
than 1) to positive (HR below 1) after adjustment for the
powerful predictors of survival, i.e., ISS and treatment status.
4. Discussion
Renal failure, which is present in approximately 30% of
newly diagnosed MM (NDMM) patients, is a major cause
of early mortality, and an independent poor prognostic factor
of survival. However, renal impairment (RI) is potentially
Table 3: Laboratory data of patients at baseline.
Characteristic MM patients (n = 73)
Serum creatinine, μmol/l 89 (76; 104)
eGFR (MDRD), ml/min/1.73m2 65.4 (49.6; 73.4)
>60ml/min/1.73m2, n (%) 47 (64)
30-60ml/min/1.73m2, n (%) 17 (23)
<30ml/min/1.73m2, n (%) 9 (12)
Hemoglobin, g/dl 12:5 ± 1:8
Anemia (hemoglobin below lower reference limit), n (%) 14 (19)
Serum iron, μmol/l 15:3 ± 4:9
Serum lactate dehydrogenase, U/l 360 ± 74
Lactate dehydrogenase above higher reference limit, n (%) 5 (7)
Serum β2-microglobulin, mg/l 2.75 (2.17; 4.20)
Serum albumin, g/l 41:7 ± 4:5
Serum-free light chains
κ, mg/l 20.1 (13.0; 52.8)
λ, mg/l 19.1 (13.5; 34.3)
Involved serum-free light chains, mg/l 38.3 (17.4; 106.0)
Urine light chains
κ, mg/l ND (ND; 30.6)
λ, mg/l ND (ND; 7.6)
Involved urine light chains, mg/l 7.8 (ND; 39.0)
NT-proBNP, pg/ml 74.8 (31.6; 287.2)
Data are shown as median (lower; upper quartile) ormean ± standard deviation unless otherwise specified. eGFR: estimated glomerular filtration rate; MDRD:
Modification of Diet in Renal Disease; MM: multiple myeloma; ND: nondetectable: NT-proBNP: N-terminal pro-B-type natriuretic peptide.
Table 4: Laboratory results in MM patients as compared to control subjects.
Test MM patients (n = 73) Controls (n = 21) p value
GDF-15, pg/ml 1259 (863; 1934) 584 (516; 762) <0.001
Interleukin 6, pg/ml 2.97 (1.61; 6.00) 0.58 (0.19; 1.13) <0.001
Hepcidin 25, ng/ml 28.8 (16.5; 44.6) 27.1 (20.0; 37.3) 0.9
Serum cystatin C, ng/ml 866 (689; 1287) 963 (874; 1038) 0.5
Urine cystatin C, ng/ml 56.0 (16.3; 105.5) 46.7 (26.5; 64.3) 0.5
Urine NGAL monomer, ng/ml 12.9 (5.7; 29.1) 8.7 (4.8; 11.0) 0.08
Data are shown as median (lower; upper quartile). GDF-15: growth differentiation factor 15; MM: multiple myeloma; NGAL: neutrophil gelatinase-associated
lipocalin.
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reversible in up to 50% of patients, which may improve long-
term outcomes [14–16]. In the present study, circulating
GDF-15 was highly correlated with markers of glomerular fil-
tration (serum creatinine and cystatin C) as well as markers
of tubular injury (urinary NGAL and cystatin C). Our salient
finding is that serum cystatin C and urinary NGAL were the
strongest and independent predictors of serum GDF-15. This
could indicate a close link between the mechanisms underly-
ing MM progression and renal complications.
Renal injury occurs from a variety of pathological mech-
anisms associated with the solubility and nephrotoxic profile
of the circulating immunoglobulins and paraproteins, which
may precipitate and form casts in distal tubules or induce a
proinflammatory and profibrotic milieu when excess light
chain endocytosis occurs [17, 18]. Lipocalin 2 (NGAL), an
acute-phase molecule with iron-chelating features, character-
ized with sensitivity to early kidney damage (particularly of
tubular origin), and cystatin C, a freely filtered, proximally
absorbed, and catabolized, nonsecreted protein, have both
been identified as novel markers of RI in MM [19]. Potential
utility in very early detection of RI may translate into prompt
treatment and renal outcome improvement, though this has
not yet been well studied [20–22]. It is noteworthy to con-
sider the “Forest Fire Theory” of Mori and Nakano, which
proposes NGAL as a marker indicative of real-time kidney
damage, derived from continuous production by inflamed
tubular cells, rather than as a consequence of nephron loss
(which would be more accurately reflected in cystatin C con-
centrations) [23]. Moreover, plasma and urinary sources of
NGAL may differ; injury in distal nephron segments leads
to secretion into the urine, while plasma concentrations
could also be derived from nonrenal sources (e.g., increased
in inflammatory states) [24]. A response to kidney insult,







































No CTx On CTx
(b)
Figure 1: Serum GDF-15 concentrations according to incremental MM disease stages with reference controls (a) and among patients
receiving no chemotherapy (CTx) treatment versus those on chemotherapy at baseline (b). Data are shown as median (horizontal line),
interquartile range (box), nonoutlier range (whiskers), and outliers (points); p value is shown for overall comparison between groups. The
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SD/PD:




















5 6 7 8 9
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(b)
Figure 2: Correlations between serum GDF-15 concentrations and involved serum free light chains (FLC) (a) and β2-microglobulin (b) in
studied patients. Light circles represent patients with complete or partial remission (CR/PR), and dark circles represent patients without
remission (stable disease or progressive disease, SD/PD). The right-skewed variables were transformed using the natural logarithm (ln) to
enhance readability. The Spearman rank-order correlation coefficients (R) in the whole studied group and the subgroups are shown with
associated p values.
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NGAL in MM, while a rise in both urinary NGAL and serum
cystatin C may be indicative of a tubular-glomerular axis
impairment, for which these molecules are respective
markers [20]. Moreover, serum cystatin C levels have been
noticed to be an independent prognostic factor for survival
and correlate with advanced ISS stage [22]. Overall, we
observed a strong relationship between novel indices of kid-
ney injury and GDF-15. This may suggest that GDF-15
shares a close relationship with ongoing and/or permanent
renal damage. In our analysis of patients on maintenance
treatment, the trends between GDF-15 and markers of injury
to kidney compartments were of strong significance and were
less pronounced in the group of nontreated patients, where
remission was more common. Whether GDF-15 is a key
player in the processes shaping kidney injury or it is inter-
twined with myeloma progression and resulting end-organ
sequelae remains to be established.
GDF-15 has been shown to increase the survival of
stroma-dependent MM cells, though it is not produced by
the neoplastic cells themselves, but rather by bone marrow
(BM) mesenchymal stem cells. These stromal cells have been
documented with an abnormal gene expression profile
(termed “tumor ME genes”), which seems to support the
malignant clone and promote its proliferation and survival
(J [25]; J. [11]). Subsequent studies have shown that BM stro-
mal cells produce GDF-15 after direct contact with tumor
cells, while GDF-15 strongly enhances their clonogenic
growth and self-renewal (T. [4]). Earlier studies in newly
diagnosed myeloma patients have established GDF-15 as a
promising molecule of prognostic significance, with the
potential to identify patients with poor response to therapy
and worse prognosis (J. [11, 26]). Our study examined an
ambulatory care sample of patients with MM, demonstrating
that serum GDF-15 concentrations are significantly associ-
ated with myeloma characteristics, even in a diverse clinical
population at various stages of disease (though the majority
was in stage I according to ISS). This is supported by the rela-
tionships apparent across different patient subgroups (remis-
sion, stable, and progressive disease), which suggests that
GDF-15 may be useful not only in the treatment-naive
patients but as an additional indicator of tumor burden,
which we postulate to reflect the underlying myeloma micro-
environment. Patients subjected to the maintenance chemo-
therapy have higher GDF-15 concentrations, with complete
remission less common in these patients (10% vs. 44%),
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(d)
Figure 3: Serum GDF-15 concentrations among patients with (n = 14) and without (n = 59) anemia (a). Data are shown as median
(horizontal line), interquartile range (box), nonoutlier range (whiskers), and outliers (points). Correlations between serum GDF-15 and
blood hemoglobin (b), serum hepcidin 25 (c), and iron (d) in the studied patients. Light circles represent patients with complete or partial
remission (CR/PR) and dark circles represent patients without remission (stable disease or progressive disease, SD/PD). The right-skewed
variables were transformed using natural logarithm (ln) to enhance readability. The Spearman rank-order correlation coefficients (R) in
the whole studied group and the subgroups are shown with associated p values.
8 Mediators of Inflammation
higher circulating GDF-15 concentrations. Indeed, the differ-
ences in GDF-15 concentrations across different study
groups were only evident when comparing complete remis-
sion with partial remission, stable, and progressive disease
(significantly lower only in CR). This may indicate that in
cases of partial vs. complete remission, the tumor microenvi-
ronment exerts a protective effect on myeloma cells, which is
reflected in circulating GDF-15 concentrations similar to sta-
ble or progressive disease. GDF-15 may be a valuable mole-
cule to investigate in biomarker-based models accounting
for the complexity of myeloma biology. The characterization
of myeloma risk and the patient phenotype, i.e., whether they
will benefit from a particular therapeutic strategy, is an
important and pragmatic aspect of management [27]. How-
ever, cytogenetic and molecular characterization is not read-
ily available or accessible in all centers; therefore, a relevant
model of disease-based biomarkers is of relevance for routine
practice.
A prior analysis of a group of 15 patients with MM
showed that significantly longer progression-free survival
was present in patients with decreasing GDF-15 levels (T.
[4]). Similarly, other studies support the relationship between
GDF-15 and prognostic significance, but the association with
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Figure 4: Serum GDF-15 concentrations among studied patients according to eGFR values: >60ml/min/1.73m2 (n = 47), 30-
60ml/min/1.73m2 (n = 17), and <30ml/min/1.73m2 (n = 9) (a). Data are shown as median (horizontal line), interquartile range (box),
nonoutlier range (whiskers), and outliers (points). Correlations between serum GDF-15 and cystatin C (b) and urine NGAL (c). Light
circles represent patients with remission, and dark circles represent patients without remission. The right-skewed variables were
transformed using natural logarithm (ln) to enhance readability. Spearman rank-order correlation coefficients (R) in the whole studied
group and the subgroups are shown with associated p values.
Table 5: Simple and multiple Cox proportional hazard regression models to predict the two-year overall survival of the studied patients with
MM.
Independent variable
Simple regression Multiple regression
Hazard ratio (95% confidence interval) p value Hazard ratio (95% confidence interval) p value
ISS II or III 5.53 (1.76-17.39) 0.003 9.12 (2.05-40.72) 0.004
On CTx treatment 13.02 (2.93-57.95) <0.001 15.02 (3.07-73.65) <0.001
ln (GDF-15) 1.99 (0.97-4.08) 0.061 0.36 (0.12-1.04) 0.060
CTx: chemotherapy; GDF-15: growth differentiation factor 15; ISS: International Staging System for multiple myeloma.
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et al. showed that lower plasma GDF-15 is associated with
better event-free and overall survival, though this was not
confirmed in subsequent studies (J. [11, 26]). However, in
the study by Westhrin et al., lower serum GDF15 was associ-
ated with improved survival, more advanced osteolytic bone
disease, and a relationship with serum measures of osteoclast
activity. Further in vitro experiments showed promotion of
osteoclast differentiation and osteoblast inhibition, which
together supports the role of GDF15 in another cardinal
myeloma feature—bone disease [9]. We were not able to con-
firm a significant association between circulating GDF-15
levels and overall two-year survival in regression models,
and remarkably, the direction of the trend was reversed after
accounting for disease stage and chemotherapy, which were
strong determinants of poor survival. GDF-15 may therefore
be a molecule reflecting myeloma burden as a consequence of
the progressive disease, and therefore, its assessment
throughout the management does not hold more favorable
prognostic significance to the staging system itself.
Following the indications from pathogenesis, we evalu-
ated whether GDF-15 shares a relationship with biomarkers
involved in the development of its cardinal features (hepcidin
as a regulatory molecule of anemia of chronic disease, IL-6 as
a major myeloma cytokine, and novel molecules of tubular
and glomerular injury). Correlations between markers of
functional nephron loss (cystatin C, eGFR formulas) and
active tubular injury (urinary NGAL) were much more pro-
nounced in patients necessitating treatment (i.e., mainte-
nance chemotherapy), which may indicate that circulating
GDF-15 reflects the symptomatic character of diseases. BM
stromal cells have been reported as a major source of inter-
leukin 6, which is a key player of inflammatory pathways in
myeloma [28, 29] and inducer of hepcidin [30], which fur-
ther emphasizes the importance of the abnormal ME. Along-
side the concept of BM “crowding out” by tumor cells, it has
been demonstrated that hematopoietic stem and progenitor
cells (particularly erythroid precursors) may be reduced from
the functional impairment, which has been tied to the
adverse tumor ME, and particularly TGFβ signaling [31].
GDF-15 may be a mediator of the tumor ME (J [25]; J. [11]).
The cellular targets and biological functions of GDF-15
are still being explored. The recent discovery of the
brainstem-restricted receptor GFRAL [32] supports a pri-
mary role of GDF-15 as a signal of somatic distress for the
central nervous system (CNS), with a regulatory effect on
metabolic and anorectic activity [33]. GDF-15 also plays a
part in the inflammatory response, and the work by the
group of Luan et al. showed a GFRAL-related central meta-
bolic adaptation via the regulation of sympathetic outflow
and triglyceride metabolism [34]. Importantly, it has also
been emphasized that the manifold actions ascribed to
GDF-15 in prior research are limited by contamination of
recombinant GDF-15 with TGFβ [33, 35, 36]. This indicates
that the previous implication of GDF-15 effects on Smad2/3
activity or TGFβRII requires caution and reappraisal [36].
On the other hand, it should also be noted that GDF-15
exerts direct effects on immune cells and its immunomodula-
tory capacity may be independent of centrally regulated
mechanisms [36]. Further understanding of whether and if
the central (GFRAL) and peripheral (local, fast-acting)
GDF-15-associated mechanisms exist and interact with mye-
loma biology is warranted.
These studies provide a preliminary rationale for study-
ing GDF-15 as a purported marker of the tumor ME in
MM. Our findings revealed a strong relationship between
serum GDF-15 concentrations and the disease spectrum
(ranging from SMM to ISS stage III MM), as well as correla-
tions between circulating GDF-15 and indices of tumor bur-
den (albumin, β2-microglobulin), which fall in line with
earlier reports ([26]; J. [11]). Patients in complete remission
had significantly lower levels of GDF-15 when comparing
with stable or progressive disease. However, these differences
were marginally significant, which may also reflect an insuf-
ficient sample among subgroups.
Recombinant GDF-15 has been reported to inhibit hema-
topoiesis, which falls in line with negative correlations
between hemoglobin and increasing levels of GDF-15
observed at present, as well as in prior works (Toshihiko
[37]; Jill Corre, Hébraud, and Bourin 2013; J. [11]). The rela-
tionship between GDF-15 and markers of impaired hemato-
poiesis was confirmed in all studied subgroups, which
confirms and extends the results of earlier studies. Moreover,
the association of hepcidin with GDF-15, which may act as a
regulatory molecule for the latter, is more pronounced in
patients with stable or progressive disease, while the trend
loses significance in remission. On the other hand, increased
GDF-15 concentrations may also reflect more advanced or
aggressive disease, which may more often lead to bone mar-
row impairment, and thus explain an association with lower
hemoglobin levels. Whether the purported roles of GDF-15
remain independent of TGFβ activity (with respect to con-
tamination of recombinant GDF) or are invalidated remains
to be confirmed. The ability of GDF-15 to regulate erythro-
poiesis through the suppression of hepcidin, the main regula-
tor of iron metabolism, has prompted further investigations,
which have implied an alternating role of GDF-15 in the con-
text of underlying stimuli (primary disease, inflammatory
milieu, and status of iron metabolism) [38]. The liver pro-
duces hepcidin in response to inflammatory cytokines, such
as interleukin 6, though this process is also influenced by iron
availability, hypoxia, and erythropoietin (EPO) [38]. In pre-
viously untreated MM patients, or those not in remission,
hepcidin and GDF-15 are overexpressed in peripheral blood
mononuclear cells, with plasma concentrations of GDF-15,
interleukin 6, EPO, and hepcidin noticeably elevated [12].
We observed that our patients had elevated levels of interleu-
kin-6, suggesting an underlying, prevalent state of inflamma-
tion, which may have modestly elevated circulating GDF-15
levels. As opposed to the inhibitory effect associated with
very high GDF-15 concentrations, moderate elevation may
stimulate hepcidin and explain the positive relationship
noted at present (Toshihiko [37]).
Induction of hepcidin by GDF-15 may potentially limit
the availability of iron for hematopoiesis and provide an
alternative explanation for the relationship with anemia. It
should be noted that the majority of our patients achieved
PR/CR and were subjected to treatment, likely decreasing
the levels of hepcidin and GDF-15, which falls in line with
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the observations from earlier studies [12]. Małyszko et al.
previously examined the relationship between iron homeo-
stasis and GDF-15 in kidney allograft recipients showing a
significant elevation of GDF-15 in patients with anemia,
while concentrations of GDF-15 and hepcidin, an indepen-
dent predictor of GDF-15, were raised overall [39].
In elderly individuals with anemia of unknown etiology,
the moderate elevation of GDF-15 was observed, the latter
being strongly correlated with kidney function (creatinine),
which was surmised to indicate a mutual relationship
between anemia and renal insufficiency [40]. Research has
revealed that intrarenal expression of GDF-15 in the tubu-
lointerstitial compartment correlates with its circulating
levels, for which an increase in the latter may independently
reflect renal function deterioration [41]. Large studies of the
Framingham community have shown that GDF-15 is associ-
ated with new-onset renal disease and the decline in kidney
function [42]. In AL amyloidosis, serum GDF-15 was
recently revealed as the most significant prognostic measure
for dialysis and a valuable addition to renal risk stratification
[43]. The underlying mechanism of GDF-15 in both MM-
and AL-related renal pathology is unclear, though in AL-
amyloidosis, it has been suggested that GDF-15 plays a direct
role in pathophysiology, and its production may be induced
following a response to free light chain toxicity [43]. Simi-
larly, we show that circulating GDF-15 correlates with the
involved monoclonal light chains, and there is a significant
relationship with involved paraproteins in urine or serum
of patients who are not subject to treatment. GDF-15 seems
to be an integral component of the tumor ME, for which it
may serve as a surrogate measure, alongside other indices
characterizing disease burden. The aforementioned studies
suggest that GDF-15 may also be a mediator of processes
involved in developing anemia and renal dysfunction, for
which an indirect measure could be attained by assaying cir-
culating forms, potentially holding diagnostic and prognostic
significance (graphical presentation in Figure 5). However, it
should be emphasized that the increased understanding of
the molecular mechanisms of GDF-15 activity, particularly
with regard to central GFRAL activity, is necessary to estab-
lish future utility.
4.1. Limitations. There are several weaknesses of the study
that have to be emphasized. Due to this study being a
single-center investigation, we recruited a heterogenous pop-
ulation in favor of study sample size, which prompted post
hoc analysis to delineate patient subgroups of clinical inter-
est. Prior studies in homogenous samples (i.e., incident mye-
loma cases) have already demonstrated that GDF-15 is a
candidate marker in myeloma, yet the majority of patients
that stand to benefit from biomarker assays throughout the
management are not treatment-naive.
5. Conclusions
We postulate that GDF-15 may parallel the underlying
mechanisms of myeloma pathology occurring in the abnor-
mal ME, and as such, it shares a relationship with tumor bur-
den and disease complications, most prominently related to
anemia and kidney injury. Due to the correlations between
GDF-15 and other markers of myeloma burden, which are
also indicators of renal injury (e.g., β2 microglobulin), it is
also conceivable that the pronounced concentrations of
GDF-15 apparent at more advanced stages of disease relate
to impaired glomerular filtration. However, the relationship
with urinary NGAL in all clinical subgroups, which is reflec-
tive of active inflammation in the tubular compartment, may
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Tumor growth and progression
Figure 5: The proposed graphical representation of the bone marrow environment in multiple myeloma and end-organ involvement:
abnormal bone marrow stromal cells release growth factors, cytokines, and survival factors (including GDF-15) following interactions
with malignant plasma cells, which leads to uncontrolled tumor growth and progression. GDF-15 is associated with the development of
the cardinal features of myeloma (anemia, renal impairment, and bone lesions), and it may be a mediator of pathways related to the
development and progression of these complications.
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tumor progression) is more mechanistically related to the cir-
culating levels of GDF-15, rather than functional nephron
loss.
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